These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 25617253

  • 1. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ, Lane R, Nuamah I, Gopal S, Hough D.
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study.
    Savitz A, Lane R, Nuamah I, Singh J, Hough D, Gopal S.
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):548-57. PubMed ID: 26218669
    [Abstract] [Full Text] [Related]

  • 3. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MG, Bilenberg N, Stenstrøm AD, Nyvang L, Madsen S, Werge TM, Lange T, Gluud C, Skoog M, Winkel P, Jepsen JRM, Fagerlund B, Correll CU, Fink-Jensen A.
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [Abstract] [Full Text] [Related]

  • 4. A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.
    Kotler M, Dilbaz N, Rosa F, Paterakis P, Milanova V, Smulevich AB, Lahaye M, Schreiner A.
    J Psychiatr Pract; 2016 Jan; 22(1):9-21. PubMed ID: 26813484
    [Abstract] [Full Text] [Related]

  • 5. Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.
    Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L.
    Int Clin Psychopharmacol; 2016 Nov; 31(6):315-22. PubMed ID: 27434314
    [Abstract] [Full Text] [Related]

  • 6. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
    Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG.
    Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
    Canuso CM, Turkoz I, Sheehan JJ, Bossie CA.
    J Affect Disord; 2010 Jan 01; 120(1-3):193-9. PubMed ID: 19552963
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM, Keating GM.
    Drugs; 2010 Jul 09; 70(10):1295-317. PubMed ID: 20568835
    [Abstract] [Full Text] [Related]

  • 16. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG, Loze JY, Forray C, Baker RA, Sapin C, Peters-Strickland T, Beillat M, Nylander AG, Hertel P, Nitschky Schmidt S, Eramo A, Hansen K, Naber D.
    Int J Neuropsychopharmacol; 2017 Jan 01; 20(1):40-49. PubMed ID: 27927736
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Zhang Y, Dai G.
    Hum Psychopharmacol; 2012 Nov 01; 27(6):605-14. PubMed ID: 24446539
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.
    Gopal S, Lane R, Nuamah I, Copenhaver M, Singh J, Hough D, Bach M, Savitz A.
    CNS Drugs; 2017 Sep 01; 31(9):797-808. PubMed ID: 28660406
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.
    Am J Geriatr Psychiatry; 2008 Jan 01; 16(1):31-43. PubMed ID: 18165460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.